Batshaw M L, Robinson M B, Hyland K, Djali S, Heyes M P
Children's Seashore House, Philadelphia, PA 19104.
Ann Neurol. 1993 Nov;34(5):676-81. doi: 10.1002/ana.410340509.
Levels of the excitotoxin quinolinic acid (QUIN) were measured in the cerebrospinal fluid of infants and children with congenital hyperammonemia. Twofold to tenfold elevations of QUIN were found in 4 neonates in hyperammonemic coma (QUIN range, 250-990 nM; control mean, 110 +/- 90 nM; p < 0.005). Similar elevations of neopterin were found (range, 24-75 nM; control mean, 9.0 +/- 4.9 nM; p < 0.005). In addition, significant elevations of QUIN were found in 14 older children with congenital hyperammonemia (mean, 50 +/- 20 vs 17 +/- 6 nM; p < 0.05). Neopterin levels were not elevated in these children. The QUIN may originate from an increase in tryptophan transport across the blood-brain barrier or from induction of indolamine-2,3-dioxygenase activity. These findings support a role for QUIN in the neuropathology of congenital hyperammonemia. They also suggest the potential utility of N-methyl-D-aspartate receptor-blocking agents or inhibitors of QUIN synthesis in the treatment of hyperammonemic coma.
对患有先天性高氨血症的婴幼儿脑脊液中的兴奋性毒素喹啉酸(QUIN)水平进行了测量。在4名处于高氨血症昏迷状态的新生儿中发现QUIN升高了两倍至十倍(QUIN范围为250 - 990 nM;对照组平均值为110 +/- 90 nM;p < 0.005)。同时发现新蝶呤也有类似升高(范围为24 - 75 nM;对照组平均值为9.0 +/- 4.9 nM;p < 0.005)。此外,在14名患有先天性高氨血症的大龄儿童中也发现QUIN显著升高(平均值为50 +/- 20 vs 17 +/- 6 nM;p < 0.05)。这些儿童的新蝶呤水平未升高。QUIN可能源于色氨酸跨血脑屏障转运增加或吲哚胺-2,3-双加氧酶活性的诱导。这些发现支持了QUIN在先天性高氨血症神经病理学中的作用。它们还表明N-甲基-D-天冬氨酸受体阻断剂或QUIN合成抑制剂在治疗高氨血症昏迷方面具有潜在效用。